FDA отзывает более 3 700 бутылок таблеток от гипертонии из-за несоответствия растворимости
Управление по контролю за продуктами и лекарствами объявило о отзыве класса II более 3 700 бутылок таблеток Ольмесартана медоксимила, Амлодипина и Гидрохлоротиазида после того, как испытания показали, что они не растворяются должным образом.
U.S. Food and Drug Administration reported that more than 3,700 bottles of blood-pressure medication were recalled nationwide after laboratory tests revealed the tablets failed to meet dissolution specifications. The recall, classified as Class II, indicates the products could cause temporary or medically reversible health issues, though the risk of serious harm is considered low.
New Jersey-based Macleods Pharma USA Inc. issued the recall on Oct. 7 for tablets containing Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in strengths of 40 mg, 10 mg and 12.5 mg. The affected packages included 3,528 bottles of 30 tablets and 216 bottles of 90 tablets.
The medications are prescribed for hypertension, according to the Mayo Clinic. No further details were provided, and attempts to obtain comment from Macleods Pharma were unsuccessful.